IFC Advisors LLC Cuts Stock Position in Thermo Fisher Scientific Inc. $TMO

IFC Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,187 shares of the medical research company’s stock after selling 28 shares during the quarter. IFC Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,292,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilson Asset Management International PTY Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 20.0% in the 2nd quarter. Wilson Asset Management International PTY Ltd. now owns 31,645 shares of the medical research company’s stock worth $12,831,000 after purchasing an additional 5,267 shares in the last quarter. Morningstar Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $1,030,000. Axxcess Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 4.5% in the 2nd quarter. Axxcess Wealth Management LLC now owns 24,817 shares of the medical research company’s stock valued at $10,063,000 after acquiring an additional 1,069 shares during the last quarter. Community Bank N.A. lifted its stake in shares of Thermo Fisher Scientific by 20.1% in the 2nd quarter. Community Bank N.A. now owns 5,312 shares of the medical research company’s stock valued at $2,154,000 after acquiring an additional 890 shares during the last quarter. Finally, Verdence Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 5.9% in the 2nd quarter. Verdence Capital Advisors LLC now owns 4,481 shares of the medical research company’s stock valued at $1,817,000 after acquiring an additional 248 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. UBS Group boosted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $589.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $524.80 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $198.17 billion, a P/E ratio of 30.35, a PEG ratio of 2.85 and a beta of 0.77. The stock’s 50 day moving average is $489.83 and its 200 day moving average is $447.66. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the business posted $5.37 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.